Dramatic Responses Seen with TRK Inhibitor [News in Brief]

Treatment with larotrectinib yielded responses in 76% of patients—pediatric and adult—regardless of tumor type.

from Cancer via ola Kala on Inoreader http://ift.tt/2rYM8fP
via IFTTT